Most Fish Oil Supplement Labels Make Health Benefit Claims
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Aug. 25, 2023 -- The majority of fish oil supplement labels make health claims and vary significantly in the recommended daily dosage, according to a study published online Aug. 23 in JAMA Cardiology.
Joanna N. Assadourian, from University of Texas Southwestern Medical Center in Dallas, and colleagues evaluated health claims made on the labels of fish oil supplements in the United States and examined doses of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in commonly available formulations. The analysis included 2,819 unique fish oil supplements in the National Institutes of Health Dietary Supplement Label Database.
The researchers found that nearly three-quarters of products (73.9 percent) made at least one health claim, yet fewer than one in five of these products (19.2 percent) used a U.S. Food and Drug Administration-approved qualified health claim. The remaining 80.8 percent made only structure/function claims (e.g., “promotes heart health”), with cardiovascular health claims being the most common (62.0 percent). Among the 16 leading brands/manufacturers (255 fish oil supplements), there was substantial variability in the daily dose of EPA (median, 340 mg/day), DHA (median, 270 mg/day), and total EPA+DHA (median, 600 mg/day). Fewer than one in 10 of the supplements (9.4 percent) contained a daily dose of ≥2 g EPA+DHA.
“Increasing regulation of dietary supplement labeling may be needed to prevent consumer misinformation,” conclude the authors.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.